A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway
Frontiers in Pharmacology · 16.11.2023 · 14
DOI: 10.3389/fphar.2023.1275749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.11.2023. Verfasst von Jeongeun Park und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inhibition of angiogenesis is considered a promising therapeutic approach for cancer treatment. Our previous genetic research showed that the use of a cell-penetrating peptide to inhibit the pleckstrin homology (PH) domain of 3-phosphoinositide-dependent kinase 1 (PDK1) was a viable approach to suppress pathological angiogenesis. Herein, we synthesized and characterized a novel small molecule, CU05-1189, based on our prior study and present evidence for the first time that this compound possesses antiangiogenic properties both in vitro and in vivo . The computational analysis showed that CU05-1189 can interact with the PH domain of PDK1, and it significantly inhibited vascular endothelial growth factor (VEGF)-induced proliferation, migration, invasion, and tube formation in human umbilical vein endothelial cells without apparent toxicity. Western blot analysis revealed that the Akt signaling pathway was specifically inhibited by CU05-1189 upon VEGF stimulation, without affecting other VEGF receptor 2 downstream molecules or cytosolic substrates of PDK1, by preventing translocation of PDK1 to the plasma membrane. We also found that CU05-1189 suppressed VEGF-mediated vascular network formation in a Matrigel plug assay. More importantly, CU05-1189 had a good pharmacokinetic profile with a bioavailability of 68%. These results led to the oral administration of CU05-1189, which resulted in reduced tumor microvessel density and growth in a xenograft mouse model. Taken together, our data suggest that CU05-1189 may have great potential and be a promising lead as a novel antiangiogenic agent for cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
- Department of Bio Research, Curacle Co., Ltd., Seoul, Republic of Korea.
- Department of Strategic Planning, Curacle Co., Ltd., Seoul, Republic of Korea.
- Department of New Drug Research Development, Curacle Co., Ltd., Seoul, Republic of Korea.
- College of Pharmacy, Gachon University, Incheon, Republic of Korea.
Zitieren
APA
Park, J., Zhang, H., Kwak, H. J., Gadhe, C. G., Kim, Y., Kim, H., Noh, M., Shin, D., Ha, S. J., & Kwon, Y. G. (2023). A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1275749
Vancouver
Park J, Zhang H, Kwak HJ, Gadhe CG, Kim Y, Kim H, et al. A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1275749
BibTeX
@article{Park2023,
author = {Park, Jeongeun and Zhang, Haiying and Kwak, Hyun Jung and Gadhe, Changdev Gorakshnath and Kim, Yeomyeong and Kim, Hyejeong and Noh, Minyoung and Shin, Dongyun and Ha, Sang-Jun and Kwon, Young-Guen},
title = {A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1275749}
}
EUVIMED